Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANFNASDAQ:OBSVNASDAQ:PCSANASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.04+0.5%$1.09$0.98▼$4.69$3.66M1.12240,437 shs107,218 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs2,500 shsPCSAHeatwurx$0.20-17.6%$0.26$0.15▼$3.10$2.33M1.394.86 million shs8.88 million shsVYNEVYNE Therapeutics$1.42-12.3%$1.19$0.85▼$4.30$21.60M1.56185,740 shs1.23 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma0.00%-1.90%-4.17%-30.01%-60.94%OBSVObsEva0.00%0.00%0.00%0.00%0.00%PCSAHeatwurx0.00%-38.71%-35.29%-49.56%-90.43%VYNEVYNE Therapeutics0.00%+59.55%+47.15%-16.47%-11.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma2.6071 of 5 stars3.75.00.00.00.00.01.3OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/APCSAHeatwurx3.8803 of 5 stars3.55.00.00.03.81.71.3VYNEVYNE Therapeutics2.7925 of 5 stars3.53.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.33Buy$14.001,252.66% UpsideOBSVObsEva 0.00N/AN/AN/APCSAHeatwurx 3.00Buy$6.002,958.10% UpsideVYNEVYNE Therapeutics 3.00Buy$6.25340.14% UpsideCurrent Analyst Ratings BreakdownLatest OBSV, PCSA, CANF, and VYNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.75 ➝ $4.504/15/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.44N/AN/A$1.76 per share0.59OBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00PCSAHeatwurxN/AN/AN/AN/A$0.46 per shareN/AVYNEVYNE Therapeutics$500K43.20N/AN/A$3.53 per share0.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APCSAHeatwurx-$11.85M-$3.08N/AN/AN/AN/A-319.56%-232.40%8/12/2025 (Estimated)VYNEVYNE Therapeutics-$39.83M-$0.99N/AN/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)Latest OBSV, PCSA, CANF, and VYNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PCSAHeatwurx-$0.77-$0.30+$0.47-$0.30N/AN/A5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/AOBSVObsEvaN/A0.610.61PCSAHeatwurxN/A2.932.93VYNEVYNE TherapeuticsN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%OBSVObsEva17.52%PCSAHeatwurx91.93%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%OBSVObsEva14.40%PCSAHeatwurx9.60%VYNEVYNE Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionablePCSAHeatwurx2011.88 million10.74 millionNot OptionableVYNEVYNE Therapeutics3015.21 million14.48 millionNot OptionableOBSV, PCSA, CANF, and VYNE HeadlinesRecent News About These CompaniesVYNE Stock Touches 52-Week Low at $0.96 Amid Market ChallengesMay 31, 2025 | investing.comVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comVYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.April 27, 2025 | nasdaq.comVYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque PsoriasisApril 27, 2025 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)April 26, 2025 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | finanznachrichten.deVYNE shares tumble after FDA clinical hold on psoriasis drug studyApril 25, 2025 | za.investing.comVyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque PsoriasisApril 25, 2025 | biospace.comBFDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concernsApril 25, 2025 | fiercebiotech.comFFDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On HoldApril 25, 2025 | benzinga.comVYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | globenewswire.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 9, 2025 | finanznachrichten.deArtiva Biotherapeutics Names New Chief Medical OfficerApril 8, 2025 | marketwatch.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | globenewswire.comH.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)March 11, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)March 7, 2025 | markets.businessinsider.comVYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2025 | finance.yahoo.comVYNE Therapeutics reports Q4 EPS (28c) vs (20c) last yearMarch 6, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBSV, PCSA, CANF, and VYNE Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.03 +0.01 (+0.49%) Closing price 06/27/2025 03:53 PM EasternExtended Trading$1.05 +0.02 (+1.45%) As of 06/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Heatwurx NASDAQ:PCSA$0.20 -0.04 (-17.63%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.20 +0.00 (+2.45%) As of 06/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.VYNE Therapeutics NASDAQ:VYNE$1.42 -0.20 (-12.35%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.44 +0.03 (+1.76%) As of 06/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
